Key statistics
On Monday, TScan Therapeutics Inc (TCRX:NMQ) closed at 1.05, 18.99% above the 52 week low of 0.8824 set on Dec 19, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 1.02 |
|---|---|
| High | 1.07 |
| Low | 1.00 |
| Bid | 1.02 |
| Offer | 1.05 |
| Previous close | 1.06 |
| Average volume | 457.09k |
|---|---|
| Shares outstanding | 56.75m |
| Free float | 52.35m |
| P/E (TTM) | -- |
| Market cap | 60.15m USD |
| EPS (TTM) | -1.12 USD |
Data delayed at least 15 minutes, as of Mar 02 2026 21:00 GMT.
More ▼
- TScan Therapeutics Completes Enrollment in Cohort C of Phase 1 ALLOHA™ Trial and Announces FDA Clearance of Investigational New Drug Applications for Heme Candidates TSC-102-A01 and TSC-102-A03
- TScan Therapeutics to Participate in the TD Cowen 46th Annual Health Care Conference
- TScan Therapeutics Announces Positive Updated Data from the ALLOHA™ Phase 1 Heme Trial at the 67th American Society of Hematology Annual Meeting and Exposition
- TScan Therapeutics to Host Virtual KOL Event to Discuss Clinical Updates from the ALLOHA™ Phase 1 Trial and Future Market Opportunities
- TScan Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
- TScan Therapeutics to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference
- TScan Therapeutics Reaches Agreement with FDA on Pivotal Study Design for TSC-101 and Announces Strategic Prioritization to Advance TSC-101 and Extend Cash Runway into H2 2027
- TScan Therapeutics Announces Upcoming Oral and Poster Presentations at the American College of Rheumatology Convergence 2025
- TScan Therapeutics to Participate in Upcoming Investor Conferences
- TScan Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
More ▼
